
News|Articles|September 1, 2007
First-time generic approvals, September 2007
First-time generic approvals: fosphenytoin for injection; pantoprazole delayed-release tablets; cefotetan for injection; cefepime for injection.
Advertisement
Key Points
Fosphenytoin for injection, eq 50 mg/mL phenytoin (equiv to Cerebyx for injection)
ABRAXIS, APOTEX, BAXTER, BEDFORD, HOSPIRA, PHARMAFORCE, TEVA, WOCKHARDT
Pantoprazole delayed-release tablets, eq 20-and 40-mg base (equiv to Protonix delayed-release tablets)
Cefotetan for injection (equiv to Cefotan [discontinued])
ABRAXIS
Cefepime for injection, 500 mg/ vial, 1 g/vial, and 2 g/vial (equiv to Maxipime for injection)
ORCHID
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
How California is rewriting the PBM playbook
3
New therapies on the way to lower Lp(a), a cardiovascular risk factor
4
National health expenditures rise 7.2% in 2024, reaching $5.3 trillion
5





















































